ABT HCV combo SVR36 in the PILOT study is down to 82% from SVR24 that was 91% http://www.abbott.com/news-media/press-releases/abbott-presents-positive-results-from-phase-2-pilot-study-of-an-interferonfree-combination-regime.htm